FrancophonIA/ELRC3.0 huggingface dataset:
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) recommended that these emergency contraceptives could continue to be used in women of all weights as the benefits were considered to outweigh the risks.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je priporočil, naj se ta urgentna kontraceptiva še naprej uporabljata pri ženskah ne glede na telesno maso, saj je ocenil, da so njune koristi večje od tveganj.
English: The CHMP recommended that the results of these studies should be included in the product information of emergency contraceptives, but that the statements on the impact of bodyweight in the product information for Norlevo should be deleted.
Slovenian: CHMP je priporočil, naj se rezultati iz teh študij vključijo v informacije o zdravilu za urgentne kontraceptive, trditve o učinku telesne mase v informacijah o zdravilu Norlevo pa naj se črtajo.
English: For levonorgestrel-containing products, some clinical studies have suggested a reduced effectiveness in women with high bodyweight, but in others no trend for a reduced effect with increasing bodyweight was observed.
Slovenian: Pri zdravilih, ki vsebujejo levonorgestrel, so nekatere klinične študije nakazale zmanjšano učinkovitost pri ženskah z visoko telesno maso, vendar pa pri drugih ni bilo zaznati trenda zmanjševanja učinka pri višji telesni masi.
English: Having assessed all the available evidence on the effectiveness of emergency contraceptives, the CHMP considered that the data available are too limited and not robust enough to conclude with certainty that contraceptive effect is reduced with increased bodyweight, as stated in the product information for Norlevo.
Slovenian: Na podlagi ocene vseh razpoložljivih dokazov o učinkovitosti urgentnih kontraceptivov je CHMP zaključil, da so razpoložljivi podatki preveč omejeni in premalo trdni, da bi lahko z gotovostjo trdili, da se kontracepcijski učinek pri višji telesni masi zmanjša, kot je navedeno v informacijah o zdravilu Norlevo.
English: It concluded that the limited data available do not support with certainty the previous conclusion that their contraceptive effect is reduced in women with high bodyweight.
Slovenian: Ugotovljeno je bilo, da omejeni podatki, ki so na voljo, ne podpirajo z gotovostjo predhodnega sklepa, da je njihov kontracepcijski učinek manjši pri ženskah z visoko telesno maso.
English: Levonorgestrel-containing emergency contraceptives are available 'over the counter' in several European countries.
Slovenian: Urgentni kontraceptivi, ki vsebujejo levonorgestrel, so na voljo brez recepta v številnih evropskih državah.
English: The available data are limited and not robust enough to support with certainty the previous conclusion of decreased contraceptive effect with increased bodyweight/BMI.
Slovenian: Razpoložljivi podatki so omejeni in premalo trdni, da bi z gotovostjo podpirali predhodni zaključek, da se kontracepcijski učinek pri višji telesni masi/ITM zmanjša.
English: The CHMP considered that, with side effects generally mild, the safety profile of emergency contraceptives is favourable and they can continue to be taken regardless of the woman's bodyweight.
Slovenian: CHMP je menil, da je varnostni profil urgentnih kontraceptivov glede na običajno mile neželene učinke ugoden in da se lahko ti še naprej jemljejo ne glede na telesno maso ženske.
English: • Women are reminded that emergency contraception is an occasional ‘rescue' method, which does not work as well as regular methods of contraception, such as the pill.
Slovenian: • Ženske se morajo zavedati, da so urgentni kontraceptivi občasna metoda „v sili“, ki ne deluje tako dobro kot redne metode kontracepcije, kot so kontracepcijske tablete.
English: They should only be used as an occasional ‘rescue' method as they do not work as well as regular contraceptive methods.
Slovenian: Urgentne kontraceptive bi morali uporabljati le kot občasno metodo „v sili“, saj ne delujejo tako dobro kot redne kontracepcijske metode.
English: The results of this analysis conflict with the results above and show no trend for a reduced efficacy with increasing bodyweight/BMI (pregnancy rate was 0.99% [CI: 0.70-1.35] in women with BMI 18.525; 0.57% [CI: 0.21-1.24] in women with BMI 25-30; and 1.17% [CI: 0.24-3.39] in women with BMI ≥30).
Slovenian: Rezultati analize se ne skladajo z zgornjimi rezultati in ne kažejo trenda zmanjševanja učinkovitosti pri višji telesni masi/ITM (odstotek nosečnosti je bil 0,99 % [IZ: 0,70-1,35] pri ženskah z ITM 18,5-25; 0,57 % [IZ: 0,21-1,24] pri ženskah z ITM 25-30; in 1,17 % [IZ: 0,24-3,39] pri ženskah z ITM ≥ 30).
English: In November 2013, following a national procedure, the product information of one emergency contraceptive containing levonorgestrel, Norlevo, was updated on the basis of results from two clinical studies to state that Norlevo is less effective in women weighing 75 kg or more and not effective in women weighing more than 80 kg. An EU-wide review was then started to assess whether similar information should be included in the product information for other emergency contraceptives that contain levonorgestrel, and for ellaOne, an emergency contraceptive that contains ulipristal acetate.
Slovenian: Vključena je bila trditev, da je zdravilo Norlevo manj učinkovito pri ženskah, ki tehtajo 75 kg ali več, in neučinkovito pri ženskah, ki tehtajo več kot 80 kg. Nato je sledil pregled po celotni EU, da bi ocenili, ali bi morali podobne informacije vključiti v informacije o zdravilu za druge urgentne kontraceptive, ki vsebujejo levonorgestrel, in za zdravilo ellaOne, urgentni kontraceptiv, ki vsebuje ulipristalacetat.
English: Emergency contraceptives are contraceptives used to prevent unintended pregnancy following unprotected sexual intercourse or contraceptive failure.
Slovenian: Urgentni kontraceptivi so kontracepcijska sredstva, ki se uporabljajo za preprečevanje neželene nosečnosti po nezaščitenem spolnem odnosu ali neučinkoviti kontracepciji.
English: • Emergency contraceptives can continue to be used to prevent unintended pregnancy in women of any weight or body mass index (BMI).
Slovenian: • Urgentni kontraceptivi se lahko še naprej uporabljajo za preprečevanje neželene nosečnosti pri ženskah ne glede na njihovo telesno maso ali indeks telesne mase (ITM).
English: • a meta-analysis of two published studies1,2, which primarily included Caucasian women, where a reduced contraceptive efficacy was observed with increased bodyweight or BMI (pregnancy rate was 0.96% [CI: 0.44-1.82] in women with BMI 18.5-25; 2.36% [CI: 1.02-4.60] in women with BMI 25-30; and 5.19% [CI: 2.62-9.09] in women with BMI ≥30).
Slovenian: • metaanalizo dveh objavljenih študij1,2, ki sta v glavnem zajeli belke in v katerih so opazili zmanjšano kontracepcijsko učinkovitost pri višji telesni masi ali ITM (odstotek nosečnosti je bil 0,96 % [IZ: 0,44-1,82] pri ženskah z ITM 18,5-25; 2,36 % [IZ: 1,02-4,60] pri ženskah z ITM 25-30; in 5,19 % [IZ: 2,62-9,09] pri ženskah z ITM ≥ 30).
English: • Emergency contraceptives can continue to be taken after unprotected intercourse or contraceptive failure, regardless of the woman's bodyweight.
Slovenian: • Urgentni kontraceptivi se lahko še naprej jemljejo po nezaščitenem spolnem odnosu ali neučinkoviti kontracepciji ne glede na telesno maso ženske.
English: • Emergency contraceptives are used to prevent unintended pregnancy following unprotected sexual intercourse or contraceptive failure.
Slovenian: • Urgentni kontraceptivi se uporabljajo za preprečevanje neželene nosečnosti po nezaščitenem spolnem odnosu ali neučinkoviti kontracepciji.
English: 4. von Hertzen H et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial.
Slovenian: Lancet 1998; 352: 428-33. 4. von Hertzen H et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial.
English: • a meta-analysis of four clinical studies that were submitted as part of the application for marketing authorisation of ellaOne6, which suggests a possible trend for a reduced contraceptive efficacy with high bodyweight or BMI, although confidence limits overlap (pregnancy rate was 1.23% [CI: 0.78
Slovenian: • metaanalizo štirih kliničnih študij, ki so bile predložene kot del vloge za izdajo dovoljenja za promet z zdravilom ellaOne6, ki kaže na možen trend zmanjševanja kontracepcijske učinkovitosti pri visoki telesni masi ali ITM, čeprav se intervali zaupanja prekrivajo (odstotek nosečnosti je bil 1,23 % [IZ: 0,78-1,84] pri ženskah z ITM 18,5-25; 1,29 % [IZ: 0,59-2,43] pri ženskah z ITM 25-30; in 2,57 % [IZ: 1,34-4,45] pri ženskah z ITM ≥ 30).
English: References.
Slovenian: Viri
English: 90 (3 x 30 x 1) capsules (unit dose) (multipack)
Slovenian: 90 (3 x 30 x 1) kapsul (za enkratni odmerek) (skupno pakiranje)
English: 30 x 1 capsules (unit dose)
Slovenian: 30 x 1 kapsula (za enkratni odmerek)
English: The final opinion was converted into a Decision by the European Commission on 19 November 2012.
Slovenian: Končno mnenje je bilo spremenjeno v sklep Evropske komisije dne 19. novembra 2012.
English: The Committee appointed Mr G. J. Schefferlie as rapporteur and Dr B. Urbain as co-rapporteur.
Slovenian: Za poročevalca je bil imenovan G. J. Schefferlie, za soporočevalca pa dr. B. Urbain.
English: The re-examination procedure started on 3 May 2012.
Slovenian: Postopek ponovne presoje se je začel 3. maja 2012.
English: The referral started on 9 March 2011.
Slovenian: Postopek se je začel 9. marca 2011.
English: On 23 March 2012, MERIAL notified the Agency of their intention to request a re-examination of the CVMP opinion of 8 March 2012.
Slovenian: 23. marca 2012 je družba MERIAL obvestila agencijo, da namerava zaprositi za ponovno presojo mnenja odbora CVMP z dne 8. marca 2012.
English: International non-proprietary names (inn): clorsulon, closantel, nitroxinil, rafoxanide and triclabendazole
Slovenian: Mednarodna nelastniška imena (INN): klorsulon, klozantel, nitroksinil, rafoksanid in triklabendazol
English: The list of product names concerned is given in Annex I. The scientific conclusions are provided in Annex II together with the amendments in the summaries of product characteristics and package leaflets in Annex III.
Slovenian: Seznam zadevnih imen zdravila je v Prilogi I. Znanstveni zaključki so podani v Prilogi II, skupaj s spremembami povzetkov glavnih značilnosti zdravila in navodil za uporabo v Prilogi III.
English: Supplementary information was provided by some of the applicants/marketing authorisation holders by 26 August 2011.
Slovenian: Nekateri predlagatelji oziroma imetniki dovoljenj za promet z zdravili so do 26. avgusta 2011 predložili dodatne informacije.
English: During its meeting of 11-13 April 2012 the CVMP appointed Dr C. Muñoz as the rapporteur and Dr E. Persson as the co-rapporteur for the re-examination procedure.
Slovenian: Na zasedanju odbora CVMP, ki je potekalo od 11. do 13. aprila 2012, je bil za poročevalca v postopku ponovne presoje mnenja imenovan dr. C. Muñoz, za soporočevalca pa dr. E. Persson.
English: The detailed grounds for the re-examination request were submitted by MERIAL on 2 May 2012.
Slovenian: Podrobne razloge za zahtevo za ponovno presojo mnenja je družba MERIAL predložila 2. maja 2012.
English: The flukicidal substances for which a maximum residue limit has not been established in milk and that are included as active substances in authorised veterinary medicinal products in the Member States (EU/EEA) are clorsulon, closantel, nitroxinil, rafoxanide and triclabendazole.
Slovenian: Snovi proti metljajem, za katere ni bila določena mejna vrednost ostankov v mleku in ki so vključene kot zdravilne učinkovine v zdravila za uporabo v veterinarski medicini, odobrena v državah članicah (EU/EGP), so klorsulon, klozantel, nitroksinil, rafoksanid in triklabendazol.
English: Oral explanations were given by MERIAL on 16 May 2012.
Slovenian: Dne 16. maja 2012 je družba MERIAL podala ustna pojasnila.
English: The CVMP was therefore requested to give its opinion as to whether measures are necessary to ensure that the use, during the non-lactating period, of veterinary medicinal products containing clorsulon, closantel, nitroxinil, rafoxanide and triclabendazole, would not lead to residues in milk that, combined with residues of these flukicidal substances from other foodstuffs, would result in consumer exposure exceeding the acceptable daily intake.
Slovenian: Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je bil naprošen za mnenje o potrebnosti ukrepov, s katerimi bi zagotovili, da uporaba zdravil za uporabo v veterinarski medicini, ki vsebujejo klorsulon, klozantel, nitroksinil, rafoksanid in triklabendazol, zunaj obdobja laktacije ne bi povzročila ostankov v mleku, ki bi v kombinaciji z ostanki teh snovi proti metljajem iz drugih živil privedli do izpostavljenosti potrošnikov, ki presega sprejemljiv dnevni vnos.
English: Written explanations were provided by a group of marketing authorisation holders on 11 January 2012.
Slovenian: Skupina imetnikov dovoljenj za promet z zdravili je 11. januarja 2012 predložila pisna pojasnila.
English: Oral explanations were given by a group of marketing authorisation holders on 8 February 2012.
Slovenian: Skupina imetnikov dovoljenj za promet z zdravili je 8. februarja 2012 podala ustna pojasnila.
English: On 14 February 2011, the European Commission initiated a referral procedure under Article 35 of Directive 2001/82/EC, as amended, for all veterinary medicinal products containing active substances belonging to the class of flukicides for which no maximum residue limit has been established in milk intended for use in all ruminants producing milk for human consumption.
Slovenian: Evropska komisija je 14. februarja 2011 začela napotitveni postopek v skladu s členom 35 Direktive 2001/82/ES, kakor je bila spremenjena, za vsa zdravila za uporabo v veterinarski medicini, ki vsebujejo zdravilne učinkovine proti metljajem, za katere ni bila določena mejna vrednost ostankov v mleku, in ki se uporabljajo pri vseh prežvekovalcih, katerih mleko je namenjeno prehrani ljudi.
English: The issues considered during the reexamination related to the recommended amendments of section 4.11 Withdrawal period(s) of the summaries of product characteristics for the veterinary medicinal products containing nitroxinil that are administered to cattle.
Slovenian: V postopku so bila obravnavana vprašanja, povezana s predlaganimi spremembami poglavja 4.11 Karenca v povzetkih glavnih značilnosti zdravil za uporabo v veterinarski medicini, ki vsebujejo nitroksinil in se dajejo govedu.
English: On 14 June 2012 the CVMP adopted a final opinion confirming the recommendation, included in its opinion of 8 March 2012, that variations are necessary in the marketing authorisations for the veterinary medicinal products containing clorsulon, closantel, nitroxinil, rafoxanide or triclabendazole as a single active substance and for the veterinary medicinal products administered as pour-on to cattle containing triclabendazole and moxidectin in order to amend the summaries of product characteristics and package leaflets in line with recommended by the CVMP changes in the product information.
Slovenian: 14. junija 2012 je odbor CVMP sprejel končno mnenje, v katerem je potrdil priporočilo iz mnenja z dne 8. marca 2012, da so potrebne spremembe dovoljenj za promet z zdravili za uporabo v veterinarski medicini, ki vsebujejo klorsulon, klozantel, nitroksinil, rafoksanid ali triklabendazol kot edino zdravilno učinkovino, in z zdravili za uporabo v veterinarski medicini, ki se dajejo govedu kot kožni poliv in vsebujejo triklabendazol ter moksidektin, da bi uskladili povzetke glavnih značilnosti zdravila in navodila za uporabo s spremembami informacij o zdravilu, ki jih je priporočil odbor CVMP.
English: Based on the evaluation of the available data, the CVMP adopted, on 8 March 2012, an opinion recommending variations of the marketing authorisations for the veterinary medicinal products containing clorsulon, closantel, nitroxinil, rafoxanide or triclabendazole as a single active substance and for the veterinary medicinal products administered as pour-on to cattle containing triclabendazole and moxidectin.
Slovenian: Na podlagi vrednotenja razpoložljivih podatkov je odbor CVMP 8. marca 2012 sprejel mnenje, v katerem je priporočil spremembo dovoljenj za promet z zdravili za uporabo v veterinarski medicini, ki vsebujejo klorsulon, klozantel, nitroksinil, rafoksanid ali triklabendazol kot edino zdravilno učinkovino, in z zdravili za uporabo v veterinarski medicini, ki se dajejo govedu kot kožni poliv in vsebujejo triklabendazol ter moksidektin.
English: Opinion following an Article 351 referral for all veterinary medicinal products containing active substances belonging to the class of flukicides for which no maximum residue limit has been established in milk and which are intended for use in ruminants producing milk for human consumption
Slovenian: Mnenje v zvezi z napotitvijo v skladu s členom 351 za vsa zdravila za uporabo v veterinarski medicini, ki vsebujejo zdravilne učinkovine proti metljajem, za katere ni bila določena mejna vrednost ostankov v mleku, in ki se uporabljajo pri vseh prežvekovalcih, katerih mleko je namenjeno prehrani ljudi
English: Opinion following an Article 35 referral for all veterinary medicinal products containing active substances belonging to the class of flukicides for which no maximum residue limit has been established in milk and which are intended for use in ruminants EMA/759491/2012
Slovenian: Mnenje v zvezi z napotitvijo v skladu s členom 35 za vsa zdravila za uporabo v veterinarski medicini, ki vsebujejo zdravilne učinkovine proti metljajem, za katere ni bila določena mejna vrednost ostankov v mleku, in ki se uporabljajo pri prežvekovalcih stran 2/2
English: The referral procedure was initiated on 13 December 2012.
Slovenian: Napotitveni postopek se je začel dne 13. decembra 2012.
English: • The Committee considered the referral under article 13(2) of Regulation No 1234/2008
Slovenian: • Odbor je obravnaval napotitev po členu 13(2) Uredbe št. 1234/2008;
English: Available from: http://www.ginasthma.org/.
Slovenian: Dostopno prek: http://www.ginasthma.org/
English: Study CT07
Slovenian: Študija CT07
English: Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2011.
Slovenian: Global Strategy for Asthma Management and Prevention (Svetovna strategija za vodenje in preprečevanje astme), Global Initiative for Asthma (Svetovna pobuda za astmo - GINA), 2011.
English: As the reference and concerned Member States were not able to reach an agreement in respect of the variation, on 23 November 2012, Germany triggered a referral under Article 13 of Commission Regulation EC No 1234/2008.
Slovenian: Ker referenčna in zadevne države članice niso mogle doseči soglasja v zvezi s spremembo, je Nemčija dne 23. novembra 2012 sprožila napotitveni postopek po členu 13 Uredbe Komisije (ES) št.
English: Overall summary of the scientific evaluation of Kantos Master and associated names (see Annex I)
Slovenian: Splošni povzetek znanstvenega vrednotenja zdravila Kantos Master in povezanih imen (glejte Prilogo I)
English: On the basis of the questions raised by Sweden the points to be considered by the CHMP were:
Slovenian: Na podlagi vprašanj, ki jih je zastavila Švedska, je moral CHMP preučiti ugotovitvi, da:
English: Post hoc analysis of data from study CT07
Slovenian: Post hoc analiza podatkov iz študije CT07
English: The concept of this “early intervention” is clearly advocated in the 2011 GINA guidelines1 where it is stated that “The benefit in preventing exacerbations appears to be the consequence of early intervention at a very early stage of a threatened exacerbation”.
Slovenian: Koncept „zgodnjega ukrepanja“ jasno zagovarjajo tudi smernice GINA1 iz leta 2011, v katerih je navedeno, da „se zdi, da so koristi pri preprečevanju eksacerbacij posledica zgodnjega ukrepanja v zelo zgodnjem obdobju možne eksacerbacije“.
English: The disease severity was based on lung function (FEV1) and use of rescue medication at entry to the study.
Slovenian: Resnost bolezni je temeljila na delovanju pljuč (FEV1) in uporabi rešilnih zdravil ob vstopu v študijo.
English: Additional supportive data
Slovenian: Dodatni spremljajoči podatki
English: However, it has never been demonstrated that a small increase in total ICS dose would have an impact on the lung function or on the clinical outcomes.
Slovenian: Vendar pa ni bilo nikoli dokazano, da je rahlo povečanje skupnega odmerka ICS vplivalo na delovanje pljuč ali na klinične izide.
English: • The Committee noted that there was no comparison with the standard of care, according to the GINA guideline.
Slovenian: • Odbor je upošteval, da ni bila izvedena primerjava s standardno oskrbo v skladu s smernicami GINA.
English: This comparability has also been confirmed in a comparative clinical study between Kantos Master and associated names (Foster 10/6) and Symbicort 200/6 (budesonide/formoterol)3.
Slovenian: Ta primerljivost je bila potrjena tudi v primerjalni klinični študiji zdravila Kantos Master in povezanih imen (Foster 10/6) in zdravila Symbicort 200/6 (budezonid/formoterol)3.
English: In addition, both components have been developed as an extrafine formulation, which means they reach the most peripheral airways where most of the inflammatory process takes place during asthma exacerbation.
Slovenian: Poleg tega sta bili obe sestavini razviti v izjemno drobni sestavi, kar pomeni, da dosežeta najbolj periferne dihalne poti, kjer se med eksacerbacijo astme odvija največ vnetnih procesov.
English: Therefore, the CHMP recommended the granting of the variation to the terms of the marketing authorisations for the medicinal products referred to in Annex I for which the valid Summary of Product Characteristics, labelling and package leaflet remain as per the final versions achieved during the Coordination group procedure as mentioned in Annex III.
Slovenian: zato je CHMP priporočil odobritev spremembe pogojev dovoljenj za promet z zdravili, navedenimi v Prilogi I, katerih povzetek glavnih značilnosti zdravila, označevanje in navodila za uporabo ostanejo enaki kot končne različice, dogovorjene med postopkom usklajevalne skupine, kakor je omenjeno v Prilogi III.
English: Significant improvements were also observed in the secondary efficacy variables (Forced Expiratory Volume in the 1st second (FEV1), asthma symptoms, medication free days etc.) in both treatment arms.
Slovenian: Pomembno izboljšanje so opazili tudi pri sekundarnih spremenljivkah učinkovitosti (forsiranem ekspiracijskem volumnu v prvi sekundi (FEV1), simptomih astme, številu dni brez zdravil itd.) v obeh skupinah, ki sta prejemali zdravljenje.
English: Both components (BDP and FF) have been shown to be effective in the case of asthma exacerbation due to their anti-inflammatory and bronchodilating effects, and their effects are enhanced if they are administered in combination.
Slovenian: Obe sestavini (BDP in FF) sta zaradi svojih protivnetnih in bronhodilatacijskih učinkov dokazano učinkoviti pri eksacerbaciji astme, njun učinek pa se še poveča, če se uporabita v kombinaciji.
English: Kantos Master has received marketing authorisation in the European Union through the Mutual Recognition Procedure (MRP).
Slovenian: Zdravilo Kantos Master je pridobilo dovoljenje za promet v Evropski uniji po postopku medsebojnega priznavanja.
English: The extrapolation of data from Symbicort SMART was questionable as the similarity of these two products in the MART regimen has not been established.
Slovenian: 2. je bila ekstrapolacija podatkov o zdravilu Symbicort SMART vprašljiva, saj ni bila dokazana podobnost med omenjenima dvema zdraviloma pri zdravljenju po shemi MART.
English: The CHMP also took into account the suitability of Kantos Master (in terms of its components and its formulation) for the MART approach.
Slovenian: CHMP je upošteval tudi primernost zdravila Kantos Master (glede na njegove sestavine in sestavo) za shemo MART.